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Objective: Dermal fibroproliferative disorders impair patients’ quality of life. Al-
though several therapeutic approaches exist for treatment of dermal scars, the devel-
opment of effective ointments with few adverse effects could improve these thera-
peutic methods. Short-chain and ω-3 polyunsaturated fatty acids are reported to be
immunomodulators with anti-inflammatory properties. Our aim was to evaluate anti-
inflammatory and antifibrogenic effects of these fatty acids in human dermal fibroblasts.
Methods: Cells were incubated with short-chain fatty acids (butyrate or propionate; 0-16
mM) and/or ω-3 polyunsaturated fatty acids (docosahexaenoic acid or eicosapentaenoic
acid; 0-100 μM) for 24 hours to evaluate antifibrogenic effects and for 3 or 48 hours to
evaluate anti-inflammatory effects after stimulation with lipopolysaccharide or without
stimulation. Expression levels of α-smooth muscle actin, collagen I, collagen III, and
IL-6 were evaluated, as were cell proliferation, stress fiber formation, and histone acety-
lation. Results: In the lipopolysaccharide-unstimulated group, butyrate inhibited mRNA
expression of α-smooth muscle actin and collagen III more effectively than propionate
and increased histone acetylation. Docosahexaenoic acid inhibited mRNA expression of
α-smooth muscle actin and collagen III, whereas eicosapentaenoic acid did not. Combin-
ing butyrate with docosahexaenoic acid had stronger effects, downregulating α-smooth
muscle actin, collagen I, and collagen III mRNA. As for cell proliferation and stress fiber




formation, butyrate acted as a stronger inhibitor than docosahexaenoic acid and the com-
bined administration had stronger effects. In the lipopolysaccharide-stimulated group,
butyrate and docosahexaenoic acid attenuated IL-6 mRNA upregulation by lipopolysac-
charide. Conclusion: Butyrate and docosahexaenoic acid may be a novel therapeutic
approach to treatment of dermal fibroproliferative disorders.
Dermal fibroproliferative disorders, such as hypertrophic scars, impair the patients’
quality of life owing to cosmetic and functional deficiencies.1 These conditions are caused
by aberrant wound healing after any injury or skin incision and are characterized by hyper-
proliferation of dermal fibroblasts and overproduction of the extracellular matrix, especially
type I collagen (collagen I) and collagen III.2 α-Smooth muscle actin (α-SMA) expression
and stress fiber formation are observed in the cytoplasm of activated fibroblasts, which
undergo intense fibrogenesis, and transforming growth factor β1 (TGF-β1) is reported to
be one of the augmenting factors of dermal fibrosis.3 Therefore, regulation of these factors
is important for preventing the progression of fibrosis. Furthermore, chronic inflamma-
tion activates the aforementioned fibrogenic responses.4 In particular, overexpression of
the IL-6 gene in hypertrophic scar fibroblasts has been reported.5 Therefore, regulation
of inflammatory responses is needed for scar management. Several therapeutic modalities
exist for preventing hypertrophic scar formation, including silicon-based products and ra-
diation therapy, and multiple therapeutic approaches are applied in response to a patient’s
symptoms.6 Although intraregional treatments using steroids or 5-fluorouracil are known to
have promising therapeutic effects,7 the adverse effects of these treatments are considered
potentially problematic.
Short-chain fatty acids (SCFAs) are the end products of anaerobic bacterial fermen-
tation of indigestible carbohydrates in the colon.8 Predominantly, butyrate and propionate
possess strong physiological activities as histone deacetylase (HDAC) inhibitors.8 We have
revealed the inhibitory effects of butyrate and propionate on nuclear factor kappa B (NF-
κB) activation in peripheral blood mononuclear cells.9 Recently, the antifibrogenic effect of
butyrate in several mesenchymal, rat pancreatic, or hepatic stellate cells was reported,10,11
revealing inhibition of cell growth, collagen III production, and α-SMA expression. How-
ever, SCFAs effective at suppression of dermal fibrogenesis are unknown.
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are primary fatty acids
among ω-3 polyunsaturated fatty acids (PUFAs) found in products derived from marine
organisms, including fish oil. Higher levels of arachidonic acid, one of the ω-6 PUFAs, have
been detected in hypertrophic scars compared with healthy dermis samples.12 Although ω-6
PUFAs possess proinflammatory effects,13 ω-3 PUFAs have anti-inflammatory effects via
their lipid mediators.14 Therefore, these fatty acids could be an effective treatment option for
dermal fibroproliferative disorders. The antifibrogenic effect of DHA in human peritoneal
fibroblasts has been reported, including inhibition of vascular endothelial growth factor and
collagen I expression.15 Although both DHA and EPA are purported to possess individual
therapeutic activities, the effectiveness of these fatty acids against dermal fibrosis remains
unclear.
We hypothesized that SCFAs and ω-3 PUFAs possess inhibitory effects on the ex-
pression of profibrotic and proinflammatory factors in dermal fibroblasts. In this study, our
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objective was to investigate the possible antifibrogenic and anti-inflammatory effects of
SCFAs (butyrate and propionate) and ω-3 PUFAs (DHA and EPA) and of their combined
administration in human dermal fibroblasts (HDFs). To evaluate the anti-inflammatory
effects, we stimulated HDFs with lipopolysaccharide (LPS; derived from Pseudomonas
aeruginosa), which is the major pathogenic factor of burn infections.16
MATERIALS AND METHODS
Cell culture
HDFs (CC-2511; Clonetics, San Diego, Calif) were grown at 37◦C and 5% CO2 in 100-mm
tissue culture dishes (Iwaki, Tokyo, Japan) containing Dulbecco’s modified Eagle’s medium
(DMEM; Dainippon Sumitomo Pharma, Osaka, Japan) supplemented with 10% of fetal
bovine serum (FBS) (Nichirei, Tokyo, Japan), penicillin (50 U/mL), and streptomycin
(50 μg/mL; MP Biomedicals, Illkirch, France). The cells at passages 5 to 8 were used for
experimentation. Because normal fibroblasts increase own α-SMA expression, stress fiber
formation, and proliferation when cultured on a plastic substrate in the presence of FBS,3
we seeded HDFs in plastic plates with 10% of FBS to evaluate the suppressive effects
of SCFAs and PUFAs on these factors. The cell concentrations were 2.8 × 105/well in
6-well flat-bottom plates (Iwaki) and 8.0 × 103/well in 96-well flat-bottom plates (Iwaki).
After 24 hours, fatty acids were added and cells were incubated for additional 24 hours to
evaluate the antifibrogenic effects because of the absence of inhibitory effects at 12 hours on
mRNA expression of profibrotic factors in our preliminary experiments. Anti-inflammatory
effects were evaluated at 3 to 48 hours after administration of LPS and fatty acids. HDFs
were subsequently processed for total RNA isolation using the TRIzol Reagent (Invitrogen,
Carlsbad, Calif) and for protein isolation using ProPrep (iNtRON, Gyeonggi-do, South
Korea). Trypan blue staining was performed to distinguish live cells from dead cells in
order to calculate cell viability.
Fatty acid administration
Sodium butyrate (Sigma-Aldrich, St Louis, Mo) and sodium propionate (Sigma-Aldrich)
served as SCFAs, whereas sodium DHA (Sigma-Aldrich) and sodium EPA (Sigma-Aldrich)
were used as ω-3 PUFAs. To evaluate single-agent administration, butyrate or propionate
was applied at a concentration of 0, 1, 4, or 16 mM and DHA or EPA was applied at a
concentration of 0, 50, or 100 μM, based on our previous in vitro studies.9,17-21 To evaluate
combined agent administration, butyrate at a concentration of 0, 1, 4, or 16 mM was applied
in combination with DHA at a concentration of 100 μM.
Proliferation assays
HDFs were seeded in 96-well plates and treated with fatty acids for 24 hours, followed




Table 1. Primers used for real-time polymerase chain reaction
Annealing,
Gene Forward (5′-3′) Reverse (5′-3′) ◦C
GAPDH CATCAAGAAGGTGGTGAAGC CCTCCCCAGCAAGAATGTCT 62.5
α-SMA CGTGGGTGACGAAGCACAG GGTGGGATGCTCTTCAGGG 62.5
TGF-β1 GGGACTATCCACCTGCAAGA CCTCCTTGGCGTAGTAGTCG 62.5
Collagen I GTGCTAAAGGTGCCAATGGT ACCAGGTTCACCGCTGTTAC 57.5
Collagen III TATCGAACACGCAAGGCTGTGAGA GGCCAACGTCCACACCAAATTCTT 65.8
IL-6 AAGCCAGAGCTGTGCAGATGAGTA TGTCCTGCAGCCACTGGTTC 60.0
Quantitative real-time polymerase chain reaction analysis
RNA concentration and purity were determined by means of absorbance at 260 and 280 nm.
First-strand cDNAs were synthesized from the isolated RNAs with the First-Strand cDNA
Synthesis System for reverse transcription-polymerase chain reaction (PCR) (Invitrogen).
cDNAs were used for subsequent quantitative real-time PCR analysis using the SYBR
Premix Ex Taq II (Takara Bio, Otsu, Japan) with appropriate primers (Table 1). The
PCR reactions were run on an iCycler IQ (Bio-Rad, Hercules, Calif) for 40 cycles at
95◦C for 30 seconds, at an annealing temperature (Table 1) for 30 seconds, and at 72◦C
for 30 seconds. Post-PCR melting curves were confirmed by the specificity of single-
target amplification. All measurements were done in duplicate. All specific quantities were
normalized to GAPDH. For each sample, the threshold cycle (Ct) was calculated on the basis
of the cycle at which the fluorescence increased above a threshold level. The Ct values were
calculated for every sample for the target genes as follows: Ct (target gene) − Ct (internal
control gene); GAPDH served as the internal control gene. The relative expression level for
1 target gene (Ct) was calculated by subtraction of the Ct of each control sample from
the Ct of each experimental sample. Finally, the relative expression value, normalized to
an endogenous reference, was calculated as 2−Ct.
Western blotting
A solution of 5 μL of the extracted protein was used to measure protein concentration by
Lowry’s method (RC DC Protein Assay Kit; Bio-Rad). Western blotting was carried out to
determine histone acetylation. In brief, samples containing equal amounts of protein were
subjected to electrophoresis in 12% polyacrylamide gels, transferred to polyvinylidene
difluoride membranes (GE Healthcare, Buckinghamshire, England), and blocked with 5%
non-fat milk. The membranes were incubated with primary antibodies against acetylated
histone (1:1000; Cell Signaling Technology Inc, Danvers, Colo) and GAPDH (1:40,000;
Sigma-Aldrich) overnight at 4◦C, followed by incubation with the appropriate horseradish
peroxidase–conjugated secondary antibody for 1 hour at room temperature. The blots were
then developed using the ECL-plus Western Blotting Detection System (GE Healthcare)
and exposed on Hyperfilm (GE Healthcare). Densitometric results were analyzed using the




Stress fibers and nuclear morphology in HDFs were analyzed by immunofluorescent stain-
ing. In this experiment, HDFs were seeded on culture cover slips (25-mm diameter; Mat-
sunami Glass Inc, Ltd, Osaka, Japan). HDFs were treated with butyrate at a concentration
of 0 or 16 mM in the presence or absence of 100 μM DHA and next were fixed in 4%
paraformaldehyde for 30 minutes, followed by immersion in a blocking solution consisting
of 1% FBS in Tris-buffered saline (TBS) for 10 minutes at room temperature. After a wash
in TBS, F-actin was labeled with phallotoxins (1:40; Invitrogen) for 20 minutes. Finally,
nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; 1:1000 dilution; Dojin,
Kumamoto, Japan). Immunofluorescent staining patterns were examined under a BX50
fluorescence microscope at ×200 magnification (Olympus, Tokyo, Japan) and recorded
with a digital camera (EOS Kiss X4; Canon, Tokyo, Japan).
Statistical analysis
The data are expressed as mean ± SEM. Differences were considered statistically significant
at P < .05, as determined by the Tukey-Kramer post hoc test.
RESULTS
Stronger inhibition of α-SMA and collagen III mRNA expression by butyrate than by
propionate in HDFs
Butyrate at concentrations of 1, 4, and 16 mM inhibited α-SMA mRNA expression in
a significant and dose-dependent manner (to 44%, 29%, and 21% of the control level,
respectively; P < .01) and collagen III mRNA expression (to 52%, 38%, and 49% of the
control level, respectively; P < .01; Figs 1a and 1b). Propionate at concentrations of 11, 4,
and 16 mM significantly inhibited collagen III mRNA expression (to 76%, 57%, and 60%
of the control level, respectively; P < .01), which is a lower degree of inhibition than that
observed with butyrate (Fig 1b). Significant differences in collagen I and TGF-β1 mRNA
expression levels were not observed (Figs 1c and 1d).
Inhibitory effects of DHA on α-SMA, TGF-β1, and collagen III mRNA expression
levels in HDFs
DHA at concentrations of 50 and 100 μM significantly inhibited mRNA expression of
TGF-β1 (to 27% and 30% of the control level, respectively; P < .05) and at a concentration
of 100 μM downregulated α-SMA (to 53% of the control level; P < .05) and collagen
III (to 65% of the control level; P < .05; Figs 2a and 2b–2d). The inhibitory effects of
100 μM DHA on collagen I mRNA expression were not significant (Fig 2c), and no
inhibitory effects of EPA were observed (Figs 2a–2d).
29
ePlasty VOLUME 19
Figure 1. The effect of SCFAs (butyrate and propionate) on mRNA expression of α-SMA (a),
collagen III (b), collagen I (c), and TGF-β1 (d) in HDFs. HDFs were exposed for 24 hours to each
SCFA at the indicated concentrations. Data from 3 independent experiments were used to calculate
mean values and SEMs. ∗∗P < .01 as compared with control cultures (Tukey-Kramer post hoc
test). SCFA indicates short-chain fatty acid; α-SMA, α-smooth muscle actin; TGF-β1, transforming
growth factor β1; and HDF, human dermal fibroblast.
Combined administration of butyrate and DHA exerts strong antifibrogenic effects
in HDFs
We expected strong inhibitory effects of the combined administration of butyrate
(1-16 mM) and DHA (100 μM). Butyrate at concentrations of 1, 4, and 16 mM com-
bined with 100 μM DHA strongly inhibited mRNA expression of α-SMA (to 27%, 25%,
and 16% of the control level, respectively; P < .01), collagen III (to 40%, 36%, and 35% of
the control level, respectively; P < .01), and collagen I at concentrations of 4 and 16 mM
(to 53% and 46% of the control level, respectively; P < .05; Figs 3a–3c). On the contrary,
the combination of butyrate and DHA did not alter mRNA expression of TGF-β1 (Fig 3d).
Next, we assessed the effects of butyrate and DHA coadministration on cell prolif-
eration (Fig 4a). Butyrate at concentrations of 4 and 16 mM significantly inhibited cell
proliferation (to 17% and 2% of the control level, respectively; P < .01). Butyrate at a
concentration of 1, 4, or 16 mM combined with 100 μM DHA significantly inhibited cell
proliferation even more than did butyrate treatment alone (to 70%, 3%, and 2% of the
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control level, respectively; P < .01). Cell counting after trypan blue staining revealed that
butyrate and DHA did not decrease cell viability, which remained more than 98% (Fig 4b).
Histone acetylation after butyrate treatment of HDFs
Butyrate at a concentration of 16 mM significantly increased histone acetylation by 10.2-
fold (P < .05), but DHA did not. Combined administration of butyrate and DHA increased
histone acetylation by 10.9-fold (P < .05) just as administration of butyrate alone did
(Fig 5a).
Figure 2. The effects of ω-3 PUFAs (DHA and EPA) on mRNA expression of α-SMA (a), collagen
III (b), collagen I (c), and TGF-β1 (d) in HDFs. HDFs were exposed for 24 hours to each ω-3 PUFA
at the indicated concentrations. Data from 3 independent experiments were used to calculate mean
values and SEMs. ∗P < .05 as compared with control cultures (Tukey-Kramer post hoc test). ω-3
PUFA indicates ω-3 polyunsaturated fatty acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic




Figure 3. The effect of butyrate combined with DHA on mRNA expression of α-SMA (a), collagen
III (b), collagen I (c), and TGF-β1 (d) in HDFs. HDFs were exposed for 24 hours to the indicated
concentrations of butyrate with 100 μM DHA or to 16 mM butyrate without DHA. Data from 3
independent experiments were used to calculate mean values and SEMs. ∗P < .05, ∗∗P < .01 as
compared with control cultures; #P < .01 in comparison with butyrate alone (Tukey-Kramer post hoc
test). DHA indicates docosahexaenoic acid; α-SMA, α-smooth muscle actin; TGF-β1, transforming
growth factor β1; and HDF, human dermal fibroblast.
Stress fiber alteration by butyrate and DHA treatment of HDFs
Immunofluorescent staining was carried out to determine the localization of stress fibers
(Fig 5b). Double staining for DNA (with DAPI) and F-actin indicated that 16 mM butyrate
and 100 μM DHA each decreased stress fiber formation in HDFs, with the effect of butyrate
being stronger. Furthermore, butyrate combined with DHA strongly disrupted stress fiber
formation in the cytoplasm. To elucidate the effects of these fatty acids on apoptosis, we
also evaluated the degree of DNA condensation and fragmentation in HDF nuclei. No
increase in DNA condensation or fragmentation was observed after the combined butyrate
+ DHA treatment for 24 or 48 hours.
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Figure 4. The effects of butyrate in the presence or absence of DHA on HDF cell
proliferation and viability. HDFs were exposed for 24 hours to the indicated con-
centrations of butyrate in the presence or absence of 100 μM DHA. The cells were
then labeled with BrdU for 24 hours, and proliferation was assessed by a BrdU DNA
incorporation assay. Data from 8 cultures were used to calculate mean values and
SEMs. ∗∗P < .01 as compared with control cultures (Tukey-Kramer post hoc test)
(a). Cell viability was determined by trypan blue staining after fatty acid incubation
for 24 hours. Data from 3 cultures were used to calculate mean values and SEMs
(b). DHA indicates docosahexaenoic acid; HDF, human dermal fibroblast; and BrdU,
5-bromo-20-deoxyuridine.
Inhibition of IL-6 and profibrotic factor expression by butyrate and DHA and
histone acetylation by butyrate in LPS-stimulated HDFs
To evaluate the anti-inflammatory effects and the relation between anti-inflammatory
and antifibrogenic effects, we analyzed IL-6 mRNA expression, which is reported to
be upregulated in hypertrophic scars, and α-SMA and collagen III expression levels,
which showed major changes under the influence of butyrate and DHA administration in
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LPS-unstimulated HDFs. In preliminary assays, significant increases in IL-6 mRNA ex-
pression were observed at 3, 6, 12, 24, and 48 hours after LPS addition to the medium.
Therefore, we evaluated the effects of 16 mM butyrate and 100 μM DHA on IL-6 ex-
pression at 3 and 48 hours. Although LPS increased IL-6 expression at 3 and 48 hours by
20.0- and 9.2-fold, respectively (P < .01), administration of butyrate alone and combined
administration of butyrate and DHA attenuated this upregulation at 3 and 48 hours (P <
.01) and DHA alone did so at 48 hours (P < .01; Figs 6a-1 and 6a-2). As for the profi-
brotic factors, 16 mM butyrate alone or combined administration of butyrate and 100 μM
DHA inhibited α-SMA (to 66% and 47% of the control level, respectively; P < .05) and
collagen III (to 10% and 8% that of control level, respectively; P < .01) expression levels;
DHA inhibited α-SMA expression (to 51% of the control level; P < .01) at 48 hours in
the LPS-stimulated HDFs compared with the control level, whereas LPS did not increase
α-SMA and collagen III expression in HDFs (Figs 6a-3 and 6a-4). Finally, we analyzed
histone acetylation at 3 and 48 hours after fatty acid administration to evaluate butyrate’s
action as an HDAC inhibitor in LPS-stimulated HDFs. Administration of butyrate alone
and combined administration of butyrate and DHA strongly increased histone acetylation
not only at 48 hours (P < .01; Fig 6b-2) but also at 3 hours (P < .05; Fig 6b-1).
Figure 5. Histone acetylation under the influence of butyrate and disruption of stress fibers by
butyrate and DHA in HDFs. HDFs were exposed to DHA (100 μM), butyrate (16 mM), or butyrate
with DHA (16 mM and 100 μM, respectively). Acetylated histone protein was analyzed by Western
blotting. A representative Western blot is shown at the top of each bar for each group and for the
internal control. The graph presents the acetylated histone/GAPDH ratio. Data from 4 independent
experiments were used to calculate mean values and SEMs. ∗P < .05 as compared with control
cultures (Tukey-Kramer post hoc test) (a). Structural organization of F-actin and nuclei in HDFs
was analyzed by immunofluorescent staining with phallotoxins (F-actin, green) and DAPI (nuclei,
blue). The displayed micrographs, obtained by means of an Olympus BX50 fluorescence microscope
at 200× magnification, are representative of all the cell cultures analyzed. Scale bar, 50 μm (b).






Figure 6. The effects of butyrate, DHA, and combined administration of butyrate and
DHA on IL-6 mRNA expression at 3 (a-1) and 48 hours (a-2), α-SMA (a-3), and collagen
III (a-4) mRNA expression levels at 48 hours, and histone acetylation at 3 (b-1) and
48 hours (b-2) after addition of each fatty acid to the culture medium. HDFs were
exposed to DHA (100 μM), butyrate (16 mM), or butyrate with DHA (16 mM and 100
μM, respectively) for 3 or 48 hours after LPS addition to the culture medium. Data from 3
independent experiments were used to calculate mean values and SEMs. ∗P < .05, ∗∗P <
.01 as compared with control cultures; #P < .05, ##P < .01 in comparison with LPS alone
(Tukey-Kramer post hoc test) (a). Acetylated histone protein was analyzed by Western
blotting. A representative Western blot is shown at the top of each bar for each group and
for the internal control. The graph presents the acetylated histone/GAPDH ratio. Data
from 4 independent experiments were used to calculate mean values and SEMs. ∗ P <
.05, ∗∗P < .01 as compared with control cultures; ##P < .01 in comparison with LPS
alone (Tukey-Kramer post hoc test) (b). DHA indicates docosahexaenoic acid; α-SMA,
α-smooth muscle actin; HDF, human dermal fibroblast; and LPS, lipopolysaccharide.
DISCUSSION
This study shows the inhibitory effects on the expressions of profibrotic factors and
proinflammatory factors by butyrate and DHA in HDFs, both individually and af-
ter combined administration. Butyrate had stronger inhibitory effects than propionate
on α-SMA and collagen III expression, along with a strong reduction in cell prolif-
eration, stress fiber formation, and LPS-induced IL-6 expression. DHA also inhibited
mRNA expression of α-SMA and collagen III and LPS-induced IL-6 mRNA expres-
sion. The combined administration of butyrate and DHA augmented the inhibitory ef-
fects of butyrate on α-SMA and collagen III mRNA expression, cell proliferation, and
stress fiber formation while decreasing the expression of collagen I mRNA. These find-
ings are suggestive of the efficacy of butyrate and DHA as a combined treatment of
dermal fibrosis.
In the present study, both butyrate and propionate exerted the inhibitory effects on
the profibrotic factor expressions in HDFs, indicating a therapeutic potential of SCFAs
against the dermal fibrotic response. The predominance of butyrate in this effect is in
agreement with the results of our previous report on NF-κB regulation in peripheral blood
mononuclear cells,9 pointing to the potency of physiological action of butyrate. Although
TGF-β1 has been shown to augment α-SMA expression,3 butyrate did not alter TGF-β1
expression here. In contrast, butyrate strongly inhibited stress fiber formation in HDFs. Be-
cause stress fiber formation upregulates α-SMA expression in fibroblasts,22 the inhibitory
effects on profibrotic factor expressions of butyrate are likely to be mediated by stress
fiber alteration rather than cytokine regulation. As for anti-inflammatory effects, inhibition
of IL-6 mRNA expression by butyrate was observed at 3 hours, as was greater histone
acetylation in LPS-stimulated HDFs. This result is consistent with the report of Grabiec
et al,23 showing IL-6 mRNA downregulation at 4 hours after administration of tricho-
statin A, a potent HDAC inhibitor. Therefore, it seems that IL-6 inhibition in the present
study is due to the HDAC inhibitory action. LPS stimulation increased IL-6 expression
36
MAESHIGE ET AL
but did not increase expression of profibrotic factors in HDFs. On the contrary, butyrate
decreased expression levels of profibrotic factors in the LPS-stimulated group compared
with the no-stimulation control. This inhibitory effect on profibrotic factors of butyrate
therefore is likely to be independent from IL-6 regulation in this in vitro experiment on
monolayer culture. However, this inhibitory action on IL-6 expression may exert thera-
peutic effects on scar tissue because the high expression of IL-6 in hypertrophic scars has
been reported.5
We revealed the inhibitory effects on not only proinflammatory factors but also profi-
brotic factors by DHA in HDFs. ω-3 PUFAs have been shown to have anti-inflammatory
effects.15 Along with these known effects, inhibition of IL-6 expression was observed in
the present study. However, the independence of the inhibitory effects on profibrotic fac-
tors from that on proinflammatory factors was demonstrated in DHA-treated HDFs and
butyrate-treated HDFs. Therefore, it appears that the inhibitory effects on profibrotic factor
expressions of DHA are mediated by the mechanisms other than inflammatory factors.
After the administration of DHA alone, TGF-β1 mRNA expression was significantly in-
hibited, as was α-SMA and collagen III mRNA expression. However, the dose dependence
of the action of DHA on the α-SMA and collagen III mRNA expression levels was not
consistent with that of TGF-β1. Therefore, regulation of TGF-β1 expression does not seem
to be the primary mechanism underlying these inhibitory effects. In the present study, the
antifibrogenic effect was exerted by DHA rather than EPA. D-series resolvins, protectins,
and maresins are lipid mediators derived from DHA but not from EPA.16 Although the
roles of these mediators in the DHA-induced inhibitory effects on profibrotic factors can be
hypothesized, the direct inhibitory effects of these mediators on fibrogenic responses have
not been demonstrated. To elucidate the mechanisms of DHA-induced inhibitory effects
on profibrotic factors, detailed experiments examining the metabolism of ω-3 PUFAs and
lipid mediators are required.
The cooperative inhibitory effect of combined butyrate and DHA administration on
profibrotic factor expressions was revealed in the present study. DHA administration not
only enhanced the antifibrogenic effects of butyrate but also inhibited collagen I mRNA
expression by approximately 50%, indicating a more potent antifibrogenic effects than
single fatty acid administration. Recently, the proapoptotic effect of combined butyrate and
DHA administration on colonocytes was demonstrated.24 In the present study, proapoptotic
morphological changes, such as DNA fragmentation or condensation, were not observed
in the fatty acid–treated fibroblasts. Therefore, further studies are necessary to reveal this
effect or its absence by means of primary culture of fibroblasts derived from pathological
tissue such as keloids.
In the present study, we revealed the inhibitory effects on profibrotic factor expressions
using the cultured human fibroblasts. Meanwhile, the mechanism of scaring in human is
very complicated.1 Therefore, we cannot determine the antifibrogenic effects of these fatty
acids in the present study. To develop the antifibrogenic therapy using these fatty acids,
future clinical studies are required.
In summary, we report the inhibitory effects on profibrotic and proinflammatory
factor expression by butyrate and DHA on HDFs, both individually and in combi-
nation. These findings can contribute to the development of novel therapies for der-
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